Literature DB >> 15236748

NOD macrophages produce high levels of inflammatory cytokines upon encounter of apoptotic or necrotic cells.

K Stoffels1, L Overbergh, A Giulietti, A Kasran, R Bouillon, C Gysemans, C Mathieu.   

Abstract

During the development of type 1 diabetes, pancreatic beta-cells are subject to an immune attack, leading to their apoptotic or necrotic cell death. Apoptotic beta-cells are also present during periods of tissue remodeling, such as in early life. Macrophages should clear apoptotic cells silently without production of pro-inflammatory cytokines. The aim of the present study was to investigate the cytokine pattern of NOD macrophages exposed to apoptotic or necrotic cells in vitro. In contrast to the limited response of macrophages from C57BL/6 or NOR mice, NOD macrophages reacted aberrantly to both necrotic and apoptotic cells, with secretion of inappropriately high amounts of IL1beta and TNFalpha. Further exploration of the macrophage behavior showed an excessive response of NOD macrophages when exposed to LPS (high iNOS and IL12p40 levels), accompanied by hyper-activation of NF-kappaB(p65). In contrast, NOD macrophages failed to up-regulate IL1beta and IL12p40 in response to IFNgamma. This failure correlated with low protein levels and a low phosphorylation state of STAT1alpha. We conclude that NOD macrophages have severely aberrant cytokine expression patterns that could contribute to the initiation or continuation of an immune attack towards the pancreatic beta-cells and thus onset and progression of type 1 diabetes. Copyright 2004 Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15236748     DOI: 10.1016/j.jaut.2004.03.012

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  19 in total

Review 1.  Resolving the conundrum of islet transplantation by linking metabolic dysregulation, inflammation, and immune regulation.

Authors:  Xiaolun Huang; Daniel J Moore; Robert J Ketchum; Craig S Nunemaker; Boris Kovatchev; Anthony L McCall; Kenneth L Brayman
Journal:  Endocr Rev       Date:  2008-07-29       Impact factor: 19.871

Review 2.  Type 1 diabetes therapy beyond T cell targeting: monocytes, B cells, and innate lymphocytes.

Authors:  F Susan Wong; Li Wen
Journal:  Rev Diabet Stud       Date:  2012-12-28

3.  Vasoactive intestinal peptide/vasoactive intestinal peptide receptor relative expression in salivary glands as one endogenous modulator of acinar cell apoptosis in a murine model of Sjögren's syndrome.

Authors:  V Hauk; M Calafat; L Larocca; L Fraccaroli; E Grasso; R Ramhorst; C Pérez Leirós
Journal:  Clin Exp Immunol       Date:  2011-12       Impact factor: 4.330

4.  Macrophages from nonobese diabetic mouse have a selective defect in IFN-γ but not IFN-α/β receptor pathway.

Authors:  Myung-Shik Lee; Hyung-Joon Kwon; Hun Sik Kim
Journal:  J Clin Immunol       Date:  2012-03-07       Impact factor: 8.317

Review 5.  Mouse models for the study of autoimmune type 1 diabetes: a NOD to similarities and differences to human disease.

Authors:  John P Driver; David V Serreze; Yi-Guang Chen
Journal:  Semin Immunopathol       Date:  2010-04-28       Impact factor: 9.623

Review 6.  Redox-Sensitive Innate Immune Pathways During Macrophage Activation in Type 1 Diabetes.

Authors:  Ashley R Burg; Hubert M Tse
Journal:  Antioxid Redox Signal       Date:  2017-11-27       Impact factor: 8.401

7.  Exaggerated Increases in Microglia Proliferation, Brain Inflammatory Response and Sickness Behaviour upon Lipopolysaccharide Stimulation in Non-Obese Diabetic Mice.

Authors:  Barry McGuiness; Sinead M Gibney; Wouter Beumer; Marjan A Versnel; Inge Sillaber; Andrew Harkin; Hemmo A Drexhage
Journal:  Neuroimmunomodulation       Date:  2016-08-17       Impact factor: 2.492

8.  Psychoneuroimmune implications of type 2 diabetes: redux.

Authors:  Jason C O'Connor; Daniel R Johnson; Gregory G Freund
Journal:  Immunol Allergy Clin North Am       Date:  2009-05       Impact factor: 3.479

9.  Nonobese diabetic (NOD) mice congenic for a targeted deletion of 12/15-lipoxygenase are protected from autoimmune diabetes.

Authors:  Marcia McDuffie; Nelly A Maybee; Susanna R Keller; Brian K Stevens; James C Garmey; Margaret A Morris; Elizabeth Kropf; Claudia Rival; Kaiwen Ma; Jeffrey D Carter; Sarah A Tersey; Craig S Nunemaker; Jerry L Nadler
Journal:  Diabetes       Date:  2007-10-16       Impact factor: 9.461

Review 10.  Autoimmune responses in T1DM: quantitative methods to understand onset, progression, and prevention of disease.

Authors:  Majid Jaberi-Douraki; Shang Wan Shalon Liu; Massimo Pietropaolo; Anmar Khadra
Journal:  Pediatr Diabetes       Date:  2014-05       Impact factor: 4.866

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.